## Yang Dong

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8987886/publications.pdf

Version: 2024-02-01

471509 526287 44 858 17 27 citations h-index g-index papers 46 46 46 1261 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Computerised tomography features of giant cell tumour of the knee are associated with local recurrence after extended curettage. International Orthopaedics, 2022, 46, 381-390.	1.9	6
2	The blood pressure and use of tourniquet are related to local recurrence after intralesional curettage of primary benign bone tumors: a retrospective and hypothesis-generating study. BMC Musculoskeletal Disorders, 2022, 23, 201.	1.9	3
3	ANGPTL4 negatively regulates the progression of osteosarcoma by remodeling branched-chain amino acid metabolism. Cell Death Discovery, 2022, 8, 225.	4.7	4
4	Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance. Biomaterials, 2021, 269, 120478.	11.4	34
5	Wnt5a promotes renal tubular inflammation in diabetic nephropathy by binding to CD146 through noncanonical Wnt signaling. Cell Death and Disease, 2021, 12, 92.	6.3	20
6	Precision Embolism: Biocompatible Temperatureâ€6ensitive Hydrogels as Novel Embolic Materials for Both Mainstream and Peripheral Vessels. Advanced Functional Materials, 2021, 31, 2011170.	14.9	10
7	Multiâ€Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation. Advanced Science, 2021, 8, e2003558.	11.2	10
8	FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53. Oncogene, 2021, 40, 2785-2802.	5.9	22
9	Sequential Release of Pooled siRNAs and Paclitaxel by Aptamer-Functionalized Shell–Core Nanoparticles to Overcome Paclitaxel Resistance of Prostate Cancer. ACS Applied Materials & Interfaces, 2021, 13, 13990-14003.	8.0	22
10	The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer. Journal of Nanobiotechnology, 2021, 19, 165.	9.1	10
11	DI-3-n-butylphthalide pretreatment attenuates renal ischemia/reperfusion injury. Biochemical and Biophysical Research Communications, 2021, 557, 166-173.	2.1	12
12	Nicotinamide retains Klotho expression and ameliorates rhabdomyolysis-induced acute kidney injury. Nutrition, 2021, 91-92, 111376.	2.4	8
13	Alpha-(1,6)-fucosyltransferase (FUT8) affects the survival strategy of osteosarcoma by remodeling TNF/NF-1ºB2 signaling. Cell Death and Disease, 2021, 12, 1124.	6.3	12
14	Efficacy and safety of Bailing capsules in the treatment of type 2 diabetic nephropathy: a meta-analysis. Annals of Palliative Medicine, 2020, 9, 3885-3898.	1.2	14
15	<p>Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma</p> . International Journal of Nanomedicine, 2020, Volume 15, 5561-5571.	6.7	8
16	Poor Renal and Cardiovascular Outcomes in Patients with Biopsy-Proven Diabetic Nephropathy. Kidney and Blood Pressure Research, 2020, 45, 378-390.	2.0	10
17	Is increased symptom interval associated with advanced stage and poorer outcome? A prospective multicenter study of 220 patients with osteosarcoma around the knee. Cancer Epidemiology, 2020, 67, 101776.	1.9	O
18	Sitagliptin ameliorates renal tubular injury in diabetic kidney disease via STAT3â€dependent mitochondrial homeostasis through SDFâ€1α/CXCR4 pathway. FASEB Journal, 2020, 34, 7500-7519.	0.5	20

#	Article	IF	Citations
19	Identification of Novel EXT Mutations in Patients with Hereditary Multiple Exostoses Using Wholeâ€Exome Sequencing. Orthopaedic Surgery, 2020, 12, 990-996.	1.8	8
20	Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway. Frontiers in Oncology, 2020, 10, 615146.	2.8	5
21	Integrated analysis of transcriptome-wide m <sup>6</sup> A methylome of osteosarcoma stem cells enriched by chemotherapy. Epigenomics, 2019, 11, 1693-1715.	2.1	73
22	Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment. Signal Transduction and Targeted Therapy, 2019, 4, 28.	17.1	75
23	Genetic Variant of (i>NFIB is Associated With the Metastasis of Osteosarcoma in Chinese Population. Technology in Cancer Research and Treatment, 2019, 18, 153303381987480.	1.9	3
24	pH-Sensitive Shell–Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast Cancer. ACS Applied Materials & Samp; Interfaces, 2019, 11, 38417-38428.	8.0	25
25	Targeting of CXCR1 on Osteosarcoma Circulating Tumor Cells and Precise Treatment via Cisplatin Nanodelivery. Advanced Functional Materials, 2019, 29, 1902246.	14.9	15
26	Ischemic Duration and Frequency Determines AKI-to-CKD Progression Monitored by Dynamic Changes of Tubular Biomarkers in IRI Mice. Frontiers in Physiology, 2019, 10, 153.	2.8	85
27	GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer. Theranostics, 2019, 9, 1047-1065.	10.0	62
28	Tumour targeted contrast enhanced ultrasound imaging dual-modal microbubbles for diagnosis and treatment of triple negative breast cancer. RSC Advances, 2019, 9, 5682-5691.	3.6	16
29	Incorporation of drug efflux inhibitor and chemotherapeutic agent into an inorganic/organic platform for the effective treatment of multidrug resistant breast cancer. Journal of Nanobiotechnology, 2019, 17, 125.	9.1	19
30	Dual-mode US/MRI nanoparticles delivering siRNA and Pt( <scp>iv</scp> ) for ovarian cancer treatment. RSC Advances, 2019, 9, 33302-33309.	3.6	4
31	Reconstruction of iliac crest defect after autogenous harvest with bone cement and screws reduces donor site pain. BMC Musculoskeletal Disorders, 2018, 19, 237.	1.9	7
32	Targeting LncRNA-MALAT1 suppresses the progression of osteosarcoma by altering the expression and localization of $\hat{l}^2$ -catenin. Journal of Cancer, 2018, 9, 71-80.	2.5	33
33	MicroRNA-16-5p Inhibits Osteoclastogenesis in Giant Cell Tumor of Bone. BioMed Research International, 2017, 2017, 1-6.	1.9	28
34	Targeting the long noncoding RNA MALAT1 blocks the pro-angiogenic effects of osteosarcoma and suppresses tumour growth. International Journal of Biological Sciences, 2017, 13, 1398-1408.	6.4	43
35	Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy. Oncotarget, 2017, 8, 111295-111308.	1.8	19
36	Alexidine Dihydrochloride Attenuates Osteoclast Formation and Bone Resorption and Protects Against LPS-Induced Osteolysis. Journal of Bone and Mineral Research, 2016, 31, 560-572.	2.8	31

#	Article	lF	Citations
37	Characterization of Micro <scp>RNA</scp> Expression Profiles in Patients with Giant Cell Tumor. Orthopaedic Surgery, 2016, 8, 212-219.	1.8	4
38	MiR-24-BIM-Smac/DIABLO axis controls the sensitivity to doxorubicin treatment in osteosarcoma. Scientific Reports, 2016, 6, 34238.	3.3	27
39	Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Biochemical Pharmacology, 2016, 104, 118-130.	4.4	24
40	Targeting Yesâ€associated Protein with Evolved Peptide Aptamers to Disrupt TGFâ€Î² Signaling Pathway: Therapeutic Implication for Bone Tumor. Molecular Informatics, 2015, 34, 771-777.	2.5	2
41	GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population. Medical Oncology, 2014, 31, 50.	2.5	24
42	Biomechanical study of modular hemipelvic endoprosthesis for Type I-IV defect of pelvic tumor. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 431-6.	2.2	0
43	Diaphyseal chondroblastoma in the tibia: One case report and literatures review. Chinese Journal of Clinical Oncology, 2008, 5, 459-461.	0.0	1
44	A case report of multiple aneurysmal bone cysts. Chinese Journal of Clinical Oncology, 2007, 4, 293-294.	0.0	O